Cover Image
市場調查報告書

勃起功能障礙:開發平台分析

Erectile Dysfunction - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 232812
出版日期 內容資訊 英文 108 Pages
訂單完成後即時交付
價格
Back to Top
勃起功能障礙:開發平台分析 Erectile Dysfunction - Pipeline Review, H2 2016
出版日期: 2016年07月30日 內容資訊: 英文 108 Pages
簡介

所謂勃起功能障礙(ED),是指男性不能維持性交必要的勃起的障礙,也稱為陽痿。易罹病素質包含有血緣和體重過剩、傷害、攝取毒品&酒精、藥物療法(抗憂鬱劑、抗組織胺藥物、高血壓治療藥、止痛藥、前列腺癌症治療藥等)等。

本報告提供全球各國的勃起功能障礙(ED)治療用的開發中產品的開發情形相關分析,產品開發、上市的最新趨勢,及臨床實驗的各階段的產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊,為您概述為以下內容。

目錄

簡介

  • 分析範圍

勃起功能障礙(ED)概要

治療藥的開發

  • 勃起功能障礙開發中產品:概要
  • 勃起功能障礙開發中產品:比較分析

各企業開發中的勃起功能障礙治療藥

大學/研究機關研究中的勃起功能障礙治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 不明確階段的產品

勃起功能障礙治療藥:開發中的產品一覽(各企業)

勃起功能障礙治療藥:研究中的產品一覽(各大學/研究機關)

開發勃起功能障礙治療藥的企業

  • Acorda Therapeutics, Inc.
  • Apricus Biosciences, Inc.
  • Biopharm GmbH
  • Corridor Pharmaceuticals Inc.
  • Futura Medical Plc
  • Hanmi Pharmaceuticals, Co. Ltd.
  • Humanetics Corporation
  • IntelGenx Corp.
  • Mezzion Pharma Co. Ltd.
  • 田邊三菱製藥
  • Monosol Rx, LLC
  • NAL Pharmaceuticals Ltd.
  • Pacific Therapeutics Ltd.
  • Palatin Technologies, Inc.
  • Pharmicell Co., Ltd.
  • Sihuan Pharmaceutical Holdings Group Ltd.
  • Suda Ltd
  • U.S. Stem Cell, Inc.
  • Yungjin Pharm. Co., Ltd.

勃起功能障礙:治療藥的評估

  • 單劑治療藥的情況
  • 並用治療藥的情況
  • 各標的
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • (PDE-5 抑制劑 + 鹽酸toramadoru)
    • 產品概要
    • 功能機制
    • 研究開發(R&D)的發展情形
  • AdipoCell
  • alprostadil
  • AP-102
  • avanafil
  • BIO-300
  • BL-214
  • cimaglermin alfa
  • fadanafil
  • HCP-1302
  • HCP-1303
  • Immpocellgram
  • MED-2005
  • 硝化甘油
  • 心血管疾病、代謝異常、勃起功能障礙治療用 G蛋白偶聯受體Mas活性肽
  • 椎間盤退化性疾病、骨折、帕金森氏症、勃起功能障礙治療用合成蛋白質
  • 檸檬酸Sildenafil
  • 血管功能障礙、 PAH、勃起功能障礙治療用精氨酸抑制劑
  • 勃起功能障礙治療用 PDE5抑制劑
  • SUD-003
  • 女性的性功能障礙、勃起功能障礙治療用黑皮質素4受體工作合成肽
  • T-6932
  • tadalafil
  • TF-0092
  • TPN-171
  • TPN-729
  • TR-399
  • udenafil
  • VLFIA-330
  • YBH-1603

勃起功能障礙治療藥:開發中產品的最新趨勢

勃起功能障礙治療藥:開發暫停的產品

勃起功能障礙治療藥:開發中止的產品

勃起功能障礙相關產品的開發里程碑

  • 值得注意的最新趨勢、新聞稿
  • ■附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8314IDB

Summary

Global Markets Direct's, 'Erectile Dysfunction - Pipeline Review, H2 2016', provides an overview of the Erectile Dysfunction pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Erectile Dysfunction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Erectile Dysfunction and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Erectile Dysfunction
  • The report reviews pipeline therapeutics for Erectile Dysfunction by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Erectile Dysfunction therapeutics and enlists all their major and minor projects
  • The report assesses Erectile Dysfunction therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Erectile Dysfunction

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Erectile Dysfunction
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Erectile Dysfunction pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Erectile Dysfunction Overview
  • Therapeutics Development
    • Pipeline Products for Erectile Dysfunction - Overview
    • Pipeline Products for Erectile Dysfunction - Comparative Analysis
  • Erectile Dysfunction - Therapeutics under Development by Companies
  • Erectile Dysfunction - Therapeutics under Investigation by Universities/Institutes
  • Erectile Dysfunction - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Erectile Dysfunction - Products under Development by Companies
  • Erectile Dysfunction - Products under Investigation by Universities/Institutes
  • Erectile Dysfunction - Companies Involved in Therapeutics Development
    • Apricus Biosciences, Inc.
    • Aytu BioScience, Inc.
    • Biopharm GmbH
    • Futura Medical Plc
    • Hanmi Pharmaceuticals, Co. Ltd.
    • Humanetics Corporation
    • IntelGenx Corp.
    • Ion Channel Innovations, LLC
    • Mezzion Pharma Co. Ltd.
    • Mitsubishi Tanabe Pharma Corporation
    • Monosol Rx, LLC
    • NAL Pharmaceuticals Ltd.
    • Palatin Technologies, Inc.
    • Pharmicell Co., Ltd.
    • Sihuan Pharmaceutical Holdings Group Ltd.
    • Suda Ltd
    • Yungjin Pharm. Co., Ltd.
  • Erectile Dysfunction - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (PDE-5 Inhibitor + tramadol hydrochloride) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • alprostadil - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AP-102 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • avanafil - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BIO-300 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BL-214 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellgram-ED - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • fadanafil - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HCP-1302 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HCP-1303 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MED-2002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MED-2005 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Peptide to Activate G Protein-Coupled Receptor Mas for Cardiovascular, Metabolic Disorders and Erectile Dysfunction - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pVAX-hSlo - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein for Bone Fracture, Degenerative Disc Disease, Erectile Dysfunction and Parkinson's Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sildenafil citrate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sildenafil citrate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sildenafil citrate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit PDE5 for Erectile Dysfunction - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SUD-003 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptide to Agonize Melanocortin 4 Receptor for Female Sexual Dysfunction and Erectile Dysfunction - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • T-6932 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tadalafil - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tadalafil - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tadalafil - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TF-0092 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TPN-729 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TR-399 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • udenafil - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VLFIA-330 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • YBH-1603 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Erectile Dysfunction - Dormant Projects
  • Erectile Dysfunction - Discontinued Products
  • Erectile Dysfunction - Product Development Milestones
    • Featured News & Press Releases
      • Mar 28, 2016: MonoSol Rx Successfully Completes Pre-IND Meeting with the FDA for PharmFilm Tadalafil
      • Nov 25, 2015: iX Biopharma Announces Success Of Pilot Bioavailability Study For Pheonix
      • Jan 29, 2015: VIVUS Announces European Approval of SPEDRA Label Amendment; SPEDRA Now First and Only Oral Erectile Dysfunction Treatment Approved in Europe to Be Taken Approximately 15 Minutes Before Sexual Activity
      • Nov 20, 2014: Auxilium Pharmaceuticals Presents STENDRA Data At SMSNA Scientific Meeting
      • Nov 03, 2014: Auxilium Pharmaceuticals To Present STENDRA Data At SMSNA Scientific Meeting
      • Sep 18, 2014: VIVUS and Auxilium Announce FDA Approval of STENDRA sNDA; STENDRA Now First and Only Oral Erectile Dysfunction Treatment Approved to Be Taken Approximately 15 Minutes Before Sexual Activity
      • Jul 09, 2014: New Grant Enables Humanetics to Evaluate Potential Treatment for Erectile Dysfunction in Prostate Cancer Patients
      • Apr 11, 2014: VIVUS To Present Clinical Data On Avanafil at European Association of Urology
      • Feb 24, 2014: IntelGenx Achieves Positive Bioequivalence Results for Erectile Dysfunction VersaFilm Tadalafil Product
      • Jan 21, 2014: VIVUS and Auxilium Announce FDA Acceptance of Supplemental Filing Seeking an Update of Prescribing Information for STENDRA (avanafil)
      • Aug 01, 2013: VIVUS Announces Commercial Supply Agreement With Sanofi to Produce Avanafil
      • Jun 26, 2013: Vivus Announces European Approval For Spedra For Treatment Of Erectile Dysfunction
      • Jun 19, 2013: Vivus Announces Positive Results From TA-501 Clinical Trial Of Stendra For Treatment Of Men With Erectile Dysfunction
      • Apr 25, 2013: Vivus Receives CHMP Positive Opinion For Spedra For Treatment Of Erectile Dysfunction In Adult Men
      • Jul 18, 2012: Zydus Urosciences Launches Udenafil For Treatment Of Erectile Dysfunction In India
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Erectile Dysfunction, H2 2016
  • Number of Products under Development for Erectile Dysfunction - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Erectile Dysfunction - Pipeline by Apricus Biosciences, Inc., H2 2016
  • Erectile Dysfunction - Pipeline by Aytu BioScience, Inc., H2 2016
  • Erectile Dysfunction - Pipeline by Biopharm GmbH, H2 2016
  • Erectile Dysfunction - Pipeline by Futura Medical Plc, H2 2016
  • Erectile Dysfunction - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2016
  • Erectile Dysfunction - Pipeline by Humanetics Corporation, H2 2016
  • Erectile Dysfunction - Pipeline by IntelGenx Corp., H2 2016
  • Erectile Dysfunction - Pipeline by Ion Channel Innovations, LLC, H2 2016
  • Erectile Dysfunction - Pipeline by Mezzion Pharma Co. Ltd., H2 2016
  • Erectile Dysfunction - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2016
  • Erectile Dysfunction - Pipeline by Monosol Rx, LLC, H2 2016
  • Erectile Dysfunction - Pipeline by NAL Pharmaceuticals Ltd., H2 2016
  • Erectile Dysfunction - Pipeline by Palatin Technologies, Inc., H2 2016
  • Erectile Dysfunction - Pipeline by Pharmicell Co., Ltd., H2 2016
  • Erectile Dysfunction - Pipeline by Sihuan Pharmaceutical Holdings Group Ltd., H2 2016
  • Erectile Dysfunction - Pipeline by Suda Ltd, H2 2016
  • Erectile Dysfunction - Pipeline by Yungjin Pharm. Co., Ltd., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Erectile Dysfunction - Dormant Projects, H2 2016
  • Erectile Dysfunction - Dormant Projects (Contd..1), H2 2016
  • Erectile Dysfunction - Dormant Projects (Contd..2), H2 2016
  • Erectile Dysfunction - Dormant Projects (Contd..3), H2 2016
  • Erectile Dysfunction - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Erectile Dysfunction, H2 2016
  • Number of Products under Development for Erectile Dysfunction - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top